Illumina Inc (ILMN)
Official siteHEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ
Market Cap: $31.30B
Last updated: Nov 17, 2026 at 11:06 AM ET
Illumina Inc (ILMN) Earnings: Report Dates and Results
Illumina (ILMN) is expected to report earnings on Feb 3, 2027. In the quarter ended Sep 30, 2026, Illumina reported EPS of $1.44, above the $1.36 estimate. It beat the EPS estimate in 7 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
ILMN has an expected report date of Feb 3, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 15.6% above the $1.35 reported for the quarter ended Dec 31, 2025.
ILMN Earnings Call
The latest ILMN earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 39 quarters below that had an estimate, ILMN beat 31, missed 7 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $1.13B, up 4.6% from $1.08B a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $1.44 | $1.36 | $1.34 - $1.38 | +5.88% | Beat | +7.5% | 19 | 1 up, 0 down | Oct 29, 2026 | $1.13B |
| Jun 30, 2026 | $1.31 | $1.23 | $1.20 - $1.26 | +6.50% | Beat | +10.1% | 17 | 2 up, 0 down | Jul 30, 2026 | $1.16B |
| Mar 31, 2026 | $1.15 | $1.06 | $1.04 - $1.08 | +8.49% | Beat | +18.6% | 17 | 0 up, 3 down | Apr 30, 2026 | $1.09B |
| Dec 31, 2025 | $1.35 | $1.23 | $1.18 - $1.29 | +9.76% | Beat | +57.0% | 16 | 3 up, 2 down | Feb 5, 2026 | $1.16B |
| Sep 30, 2025 | $1.34 | $1.17 | $1.12 - $1.19 | +14.53% | Beat | +17.5% | 18 | 2 up, 4 down | Oct 30, 2025 | $1.08B |
| Jun 30, 2025 | $1.19 | $1.01 | $0.96 - $1.05 | +17.82% | Beat | +230.6% | 20 | 4 up, 0 down | Jul 31, 2025 | $1.06B |
| Mar 31, 2025 | $0.97 | $0.94 | $0.83 - $0.97 | +3.19% | Beat | +977.8% | 19 | 4 up, 4 down | May 8, 2025 | $1.04B |
| Dec 31, 2024 | $0.86 | $0.92 | $0.91 - $0.93 | -6.52% | Miss | +514.3% | 10 | 1 up, 0 down | Feb 6, 2025 | $1.10B |
| Sep 30, 2024 | $1.14 | $0.88 | $0.84 - $0.97 | +29.55% | Beat | +245.5% | 20 | 2 up, 1 down | Nov 4, 2024 | $1.08B |
| Jun 30, 2024 | $0.36 | $0.90 | $0.83 - $0.96 | -60.00% | Miss | +12.5% | 10 | 4 up, 1 down | Aug 6, 2024 | $1.11B |
| Mar 31, 2024 | $0.09 | $0.11 | -$0.11 - $0.25 | -18.18% | Miss | +12.5% | 15 | 2 up, 0 down | May 2, 2024 | $1.08B |
| Dec 31, 2023 | $0.14 | $0.12 | -$0.11 - $0.18 | +16.67% | Beat | 0.0% | 16 | 8 up, 0 down | Feb 8, 2024 | $1.12B |
| Sep 30, 2023 | $0.33 | $0.14 | -$0.03 - $0.20 | +135.71% | Beat | -2.9% | 16 | 0 up, 2 down | Nov 9, 2023 | $1.12B |
| Jun 30, 2023 | $0.32 | $0.02 | $0.00 - $0.08 | N/A | N/A | -43.9% | 14 | 0 up, 0 down | Aug 9, 2023 | $1.18B |
| Mar 31, 2023 | $0.08 | $0.03 | $0.00 - $0.12 | +166.67% | Beat | -92.5% | 15 | 0 up, 0 down | Apr 25, 2023 | $1.09B |
| Dec 31, 2022 | $0.14 | $0.19 | -$0.23 - $0.48 | -26.32% | Miss | -81.3% | 16 | 2 up, 3 down | Feb 7, 2023 | $1.08B |
| Sep 30, 2022 | $0.34 | $0.30 | $0.21 - $0.48 | +13.33% | Beat | -76.6% | 15 | 0 up, 0 down | Nov 3, 2022 | $1.11B |
| Jun 30, 2022 | $0.57 | $0.64 | $0.53 - $0.89 | -10.94% | Miss | -69.5% | 15 | 0 up, 0 down | Aug 11, 2022 | $1.16B |
| Mar 31, 2022 | $1.07 | $0.89 | $0.75 - $0.98 | +20.22% | Beat | -43.4% | 13 | 0 up, 0 down | May 5, 2022 | $1.22B |
| Dec 31, 2021 | $0.75 | $0.49 | $0.32 - $0.62 | +53.06% | Beat | -38.5% | 16 | 6 up, 0 down | Feb 10, 2022 | $1.20B |
| Sep 30, 2021 | $1.45 | $1.22 | $0.89 - $1.36 | +18.85% | Beat | +42.2% | 11 | N/A | Nov 4, 2021 | $1.11B |
| Jun 30, 2021 | $1.87 | $1.36 | $1.31 - $1.41 | +37.50% | Beat | +201.6% | 17 | N/A | Aug 5, 2021 | $1.13B |
| Mar 31, 2021 | $1.89 | $1.40 | $1.17 - $1.94 | +35.00% | Beat | +15.2% | 17 | N/A | Apr 27, 2021 | $1.09B |
| Dec 31, 2020 | $1.22 | $1.11 | $1.01 - $1.23 | +9.91% | Beat | -28.2% | 17 | N/A | Feb 11, 2021 | $953.00M |
| Sep 30, 2020 | $1.02 | $0.80 | $0.67 - $0.89 | +27.50% | Beat | -47.2% | 16 | N/A | Oct 29, 2020 | $794.00M |
| Jun 30, 2020 | $0.62 | $0.67 | $0.33 - $1.06 | -7.46% | Miss | -54.1% | 16 | N/A | Aug 6, 2020 | $633.00M |
| Mar 31, 2020 | $1.64 | $1.25 | $1.17 - $1.32 | +31.20% | Beat | +2.5% | 16 | N/A | Apr 30, 2020 | $859.00M |
| Dec 31, 2019 | $1.70 | $1.58 | $1.55 - $1.64 | +7.59% | Beat | +28.8% | 17 | N/A | Jan 29, 2020 | $952.00M |
| Sep 30, 2019 | $1.93 | $1.41 | $1.34 - $1.48 | +36.88% | Beat | +27.0% | 14 | N/A | Oct 24, 2019 | $907.00M |
| Jun 30, 2019 | $1.35 | $1.34 | $1.13 - $1.70 | +0.75% | Beat | -5.6% | 15 | N/A | Jul 29, 2019 | $838.00M |
| Mar 31, 2019 | $1.60 | $1.35 | $1.27 - $1.39 | +18.52% | Beat | +10.3% | 15 | N/A | Apr 25, 2019 | $846.00M |
| Dec 31, 2018 | $1.32 | $1.36 | $1.32 - $1.47 | -2.94% | Miss | -8.3% | 16 | N/A | Jan 29, 2019 | $1.50B |
| Sep 30, 2018 | $1.52 | $1.26 | $1.17 - $1.40 | +20.63% | Beat | +36.9% | 18 | N/A | Oct 23, 2018 | $853.00M |
| Jun 30, 2018 | $1.43 | $1.11 | $1.07 - $1.16 | +28.83% | Beat | +74.4% | 18 | N/A | Jul 30, 2018 | $830.00M |
| Mar 31, 2018 | $1.45 | $1.02 | $0.85 - $1.09 | +42.16% | Beat | +126.6% | 18 | N/A | Apr 24, 2018 | $154.00M |
| Dec 31, 2017 | $1.44 | $1.21 | $1.14 - $1.33 | +19.01% | Beat | +69.4% | 18 | N/A | Jan 30, 2018 | $778.00M |
| Sep 30, 2017 | $1.11 | $0.99 | $0.92 - $1.07 | +12.12% | Beat | +14.4% | 17 | N/A | Oct 24, 2017 | $714.00M |
| Jun 30, 2017 | $0.82 | $0.69 | $0.64 - $0.75 | +18.84% | Beat | -4.7% | 17 | N/A | Aug 1, 2017 | $662.00M |
| Mar 31, 2017 | $0.64 | $0.64 | N/A | 0.00% | In line | -9.9% | N/A | N/A | Apr 25, 2017 | $598.00M |
| Dec 31, 2016 | $0.85 | $0.83 | N/A | +2.41% | Beat | +4.9% | N/A | N/A | Jan 31, 2017 | $619.00M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $4.85, up 98.0% from the year before. It was $3.39 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $4.85 | +98.0% |
| Dec 31, 2024 | $2.45 | +181.6% |
| Dec 31, 2023 | $0.87 | -59.0% |
| Dec 31, 2022 | $2.12 | -64.4% |
| Dec 31, 2021 | $5.96 | +32.4% |
| Dec 31, 2020 | $4.50 | -31.6% |
| Dec 31, 2019 | $6.58 | +15.0% |
| Dec 31, 2018 | $5.72 | +42.6% |
| Dec 31, 2017 | $4.01 | +18.3% |
| Dec 31, 2016 | $3.39 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 8,000 words across 16 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 7,994 | 16 | |
| 2026Q2 | Jun 30, 2026 | 6,415 | 14 | |
| 2026Q1 | Mar 31, 2026 | 7,721 | 18 | |
| 2025Q4 | Dec 31, 2025 | 7,517 | 13 | |
| 2025Q3 | Sep 30, 2025 | 7,285 | 16 | |
| 2025Q2 | Jun 30, 2025 | 6,178 | 11 | |
| 2025Q1 | Mar 31, 2025 | 7,261 | 13 | |
| 2024Q4 | Dec 31, 2024 | 8,499 | 17 |
2026Q3 Earnings Call
Opening remarks
Conor McNamara Head of Investor Relations Hello, everyone, and welcome to Illumina's third quarter 2026 earnings call. Today, we will review our financial results released after the market close and provide prepared remarks before opening the line for Q&A. Our earnings release is available in the investor relations section of illumina.com. Joining me today are Jacob Thaysen, Chief Executive Officer, and Ankur Dhingra, Chief Financial Officer. Jacob will begin with an update on Illumina's business, followed by Ankur's review of our financials. As you may have seen in our press release, we recognized certain tariff refunds in the third quarter, which had a positive impact on GAAP and non-GAAP operating income, margins, and EPS, and a negative impact on revenue. These refunds were not contemplated in our previous guidance, and all financial measures discussed today will be on an adjusted non-GAAP basis, excluding the impact of tariff refunds. Reconciliations to non-GAAP and GAAP can be found in today's release and in the supplementary data on our website. All revenue and revenue growth rates are presented excluding tariff refunds. Organic revenue growth also adjusts for the impact of currency and acquisitions, and rest-of-world organic growth further excludes our Greater China region. This call is being recorded, and the replay will be available on our website. As a reminder, the information provided and discussed today will include forward-looking statements, including statements about Illumina's future events, product outlook, and financial expectations. Actual results may differ materially. To better understand the risks and uncertainties that could cause actual results to differ, we refer you to the documents that Illumina files with the SEC, including our most recent Forms 10-Q and 10-K. With that, I will now turn the call over to Jacob.
Jacob Thaysen CEO Thank you, Conor, and good afternoon, everyone. We had a great third quarter with strong clinical sequencing demand and elevated NovaSeq X placements, driving revenue, margin, and EPS above our guidance range. Our strategy is working, and I'm proud of what our team delivered for our customers and shareholders. Our continued disciplined execution and business momentum allow us to raise our fiscal year guidance, and we remain on track to achieve our long-range financial targets. Before I go into details on our results, I want to highlight a few ways our innovation is helping customers answer new questions about biology. Early in 2026, we introduced the Billion Cell Atlas to address one of the biggest bottlenecks in applying AI to biology: the lack of functional data sets. AI models need large amounts of data to learn from. In biology, those models only work if the data is accurate, standardized, and reproducible. These data sets don't exist at scale. There is no internet of biology.
Frequently Asked Questions About ILMN
When is Illumina's next earnings date?
Illumina's next earnings report is expected for Feb 3, 2027.
Did ILMN beat earnings estimates last quarter?
Yes. Illumina reported EPS of $1.44 for the quarter ended Sep 30, 2026, above the $1.36 estimate, a 5.88% surprise.
What EPS do analysts expect from ILMN next quarter?
The consensus EPS estimate for Illumina for the quarter ending Dec 31, 2026 is $1.56 from 20 analysts, with estimates from $1.48 to $1.64.
How often does ILMN beat earnings estimates?
Illumina beat the EPS estimate in 7 of the last 8 quarters, with an average surprise of +7.46%.
ILMN pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts